GSK (LON:GSK) Share Price Passes Above 200 Day Moving Average – Should You Sell?

GSK plc (LON:GSK)’s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,980.11 and traded as high as GBX 1,990.50. GSK shares last traded at GBX 1,979.50, with a volume of 4,305,542 shares trading hands.

Analysts Set New Price Targets

GSK has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a research report on Monday, June 8th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Citigroup reduced their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Berenberg Bank restated a “hold” rating and set a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research report on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of GBX 2,034.29.

GSK Stock Performance

The firm has a market cap of £79.29 billion, a price-to-earnings ratio of 13.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. The firm’s 50 day moving average is GBX 1,924.01 and its 200-day moving average is GBX 1,980.11. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79.

GSK (LON:GSK) last posted its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The firm had revenue of GBX 762.90 billion during the quarter. Sell-side analysts anticipate that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds bought 1,550 shares of the firm’s stock in a transaction that occurred on Friday, June 19th. The stock was purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50. Also, insider Wendy Becker bought 4,000 shares of the stock in a transaction on Wednesday, April 29th. The stock was acquired at an average cost of GBX 1,963 per share, for a total transaction of £78,520. In the last ninety days, insiders purchased 7,630 shares of company stock valued at $21,357,859. 0.20% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.